Also found in: Wikipedia.



Pharmacologic class: Interleukin-1 (IL-1) blocker

Therapeutic class: Immunomodulator, antirheumatic

Pregnancy risk category B


Inhibits binding of IL-1 with IL type I receptors, thereby mediating immunologic, inflammatory, and other physiologic responses


Prefilled glass syringes: 100 mg/0.67 ml

Indications and dosages

Moderately to severely active rheumatoid arthritis in patients ages 18 and older who don't respond to disease-modifying antirheumatics alone

Adults: 100 mg/day subcutaneously, given at same time each day


• Hypersensitivity to drug or Escherichia coli-derived protein
• Serious infections


Use cautiously in:
• immunosuppression, active infection, chronic illness, renal impairment
• elderly patients
• pregnant or breastfeeding patients
• children.


Withhold drug and notify prescriber if patient shows signs or symptoms of active infection.

Use extreme caution if patient is concurrently receiving drugs that block tumor necrosis factor (TNF), because of increased risk of serious infection.
• Give entire dose from prefilled syringe.
• Don't freeze or shake syringe.

Adverse reactions

CNS: headache

EENT: sinusitis

GI: nausea, diarrhea, abdominal pain

Hematologic: thrombocytopenia, neutropenia

Respiratory: upper respiratory tract infection

Skin: rash, pruritus, injection site reaction or bruising, rash, erythema, inflammation

Other: flulike symptoms, infections


Drug-drug.Etanercept, infliximab, other drugs that block TNF: increased risk of serious infection

Live-virus vaccines: vaccine inefficacy

Drug-diagnostic tests.Neutrophils: decreased count

Patient monitoring

• Monitor CBC with white cell differential.
• Assess injection site for reactions.

Patient teaching

Tell patient to immediately report signs or symptoms of infection.
• Advise patient to report signs and symptoms of allergic response.
• Instruct patient to take drug at same time each day for best response.
• Teach patient about proper drug disposal (in puncture-resistant container). Also caution him against reusing needles, syringes, and drug product.
• Tell patient not to freeze or shake drug.
• As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs and tests mentioned above.


an antirheumatic agent and immunomodulator used to reduce the signs and symptoms of moderate to severe active rheumatoid arthritis in adults.


A human INTERLEUKIN-1-receptor antagonist used to combat the pro-inflammatory interleukins in RHEUMATOID ARTHRITIS. A brand name is Kineret.


interleukin-1-inhibiting agent, used in conjunction with methotrexate to treat non-methotrexate-responsive rheumatoid arthritis
References in periodicals archive ?
An increased risk of serious infections has been seen in clinical trials of other TNF blocking agents used in combination with anakinra or abatacept.
Recently, positive results have been observed in randomized studies of simvastatin, anakinra, thalidomide, and etanercept.
Contract award: Contract for an Anakinra Homecare Service for a 3 year period with the option to extend for up to a further 2 years.
Two other biologic agents, the interleukin (IL)-1 receptor antagonist anakinra and the IL-12/23 inhibitor ustekinumab, also have been reported to be helpful in HS.
Anakinra and Other Anti-IL Therapeutics Interleukin-1 Beta (IL-1P) has been implicated in the pathogenesis of SJIA.
2) Many antiinflammatory biological mediators, such as infliximab, etanercept, and anakinra are being tried, but there are no randomized controlled trials demonstrating effectiveness.
Agent mo Agent(s) mo no 1 NA NA Cyclophosphamide, 120 methotrexate, corticosteroids 2 NA NA Methotrexate, 120 corticosteroids 3 NA NA Chlorambucil, 36 corticosteroids 4 NA NA Methotrexate, 120 corticosteroids 5 NA NA Cyclophosphamide, 2 corticosteroids 6 Infliximab 9 No details given 300 7 NA NA Cyclophosphamide, 36 corticosteroids 8 Infliximab 12 Azathioprine, 12 corticosteroids 9 Adalimumab 25 Methotrexate, 360 corticosteroids 10 Etanercept 18 ([dagger] Cyclosporine, 96 corticosteroids, anakinra 11 NA NA Cyclosporine, 60 methotrexate, corticosteroids, anakinra 12 Infliximab 60 Methotrexate, 60 corticosteroids 13 NA NA Methotrexate 96 14 Infliximab 24 Methotrexate, 24 corticosteroids 15 Infliximab 12 Methotrexate 12 Form of Patient Leishmania no.
A multicentre, double blind, randomised, placebo controlled trial of anakinra (Kineret), a recombinant interleukin 1 receptor antagonist, in patients with rheumatoid arthritis treated with background methotrexate.
Biologic DMARDs include three agents that inhibit TNF-[alpha]--adalimumab (Humira), etanercept (Enbrel), and infliximab (Remicade)--and one interleukin-1 receptor antagonist, anakinra (Kineret).
However, in vitro observations indicate that anakinra is required in 100-fold excess of IL-1 to achieve 50% reduction in IL-1--dependent biological actions and that may be clinically challenging.